Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia
The purpose of this study is to determine the safety and effectiveness of INNO-406 in adult patients with imatinib-resistant or intolerant Philadelphia chromosome-positive (Ph+) leukemias.
Chronic Myeloid Leukemia|Acute Lymphocytic Leukemia
DRUG: INNO-406
To determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of INNO-406 when administered as a single agent to adult patients with imatinib-resistant or intolerant Ph+ leukemias., One year|To determine the safety profile (including acute and chronic toxicities) and tolerability of INNO-406 in this patient population., One year
To determine the pharmacokinetic (PK) profile of INNO-406., One year|To assess BCR-ABL transcript levels and to analyze BCR-ABL mutations., One year|To assess leukemia response rates in this patient population., One year
The purpose of this study is to determine the safety, tolerability and pharmacokinetic profile of INNO-406 when administered as a daily oral agent in adult patients with imatinib-resistant or intolerant Philadelphia chromosome-positive (Ph+) leukemias.